Christopher Simkins
Psychiatric/Mental Health · Millville, NJNPI 1992977854
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.1% of the total across 458 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 19.8% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $3,076, 8.8 times the $351 reported in 2021. Among psychiatric/mental health clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 458 payments — averaging $17.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- AbbVie$2K
- Otsuka America Pharmaceutical, Inc.$872
- Alkermes, Inc.$775
- E.r. Squibb & Sons, L.L.C.$642
- Neurocrine Biosciences, Inc.$609
- plus $2K from 14 others
What the payments were for
- Food & beverage$7,97798%
- Education$1562%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 75 | $1,608 |
| AbbVie | 93 | $1,542 |
| Otsuka America Pharmaceutical, Inc. | 46 | $872 |
| Alkermes, Inc. | 47 | $775 |
| E.r. Squibb & Sons, L.L.C. | 27 | $642 |
| Neurocrine Biosciences, Inc. | 43 | $609 |
| Teva Pharmaceuticals USA, Inc. | 38 | $598 |
| Axsome Therapeutics, Inc. | 25 | $474 |
| Supernus Pharmaceuticals, Inc. | 18 | $273 |
| Johnson & Johnson | 13 | $228 |
| Vanda Pharmaceuticals Inc. | 13 | $200 |
| Lundbeck LLC | 10 | $152 |
| Sage Therapeutics, LLC | 3 | $46 |
| Almatica Pharma LLC | 1 | $22 |
| Lilly USA, LLC | 1 | $20 |
| Sunovion Pharmaceuticals Inc. | 1 | $17 |
| Merck | 1 | $16 |
| GSK | 1 | $15 |
| AstraZeneca | 1 | $13 |
| Noven Therapeutics, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,134 in reported general payments places this provider in the 95th percentile of 1,212 psychiatric/mental health providers in New Jersey.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 253 | $355,323 |
| Invega SustennaPaliperidone Palmitate | 68 | $235,946 |
| IngrezzaValbenazine Tosylate | 24 | $185,303 |
| CaplytaLumateperone Tosylate | 40 | $64,580 |
| LybalviOlanzapine/Samidorphan Malate | 32 | $47,319 |
| RexultiBrexpiprazole | 28 | $39,708 |
| AuvelityDextromethorphan Hbr/Bupropion | 18 | $21,927 |
| Risperidone ErRisperidone Microspheres | 13 | $20,521 |
| Aripiprazole | 248 | $19,915 |
| Clozapine | 124 | $10,754 |
| Quetiapine Fumarate | 474 | $8,423 |
| Olanzapine | 481 | $7,083 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 188 | $4,609 |
| VyvanseLisdexamfetamine Dimesylate | 12 | $4,437 |
| Haloperidol Decanoate | 61 | $4,184 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $1,542 | $355,323253 claims |
| Johnson & JohnsonInvega Sustenna | $228 | $235,94668 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $609 | $185,30324 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,608 | $64,58040 claims |
| Alkermes, Inc.Lybalvi | $775 | $47,31932 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $872 | $39,70828 claims |
| Axsome Therapeutics, Inc.Auvelity | $474 | $21,92718 claims |
| Lilly USA, LLCOlanzapine | $20 | $7,083481 claims |
| Almatica Pharma LLCSertraline Hcl | $22 | $1,382212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,212 psychiatric/mental health providers in New Jersey.
Other psychiatric/mental health in Millville
- Ubong UdofiaMarlton$407K
- Anthony DimuraRed Bank$130K
- Amy PinsenNewton$111K
- Aaron SpectorMarlton$100K
- Fiorella ParadisiSparta$84K
- Diane BurtBridgeton$81K
- Alta ManessHackensack$75K
- Laura LeahySewell$41K
- Linda WinfulMontclair$40K
- Marisa SavicOradel$38K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.